Clin2
NCT06103760Possibly a fitRecruiting

Esketamine for hard-to-treat depression

Major Depressive Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
162 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with major depressive disorder and are currently depressed.
  • You have tried at least two different antidepressants at the right dose and duration, but they didn't work well enough.
  • You are willing to keep taking your current antidepressant or continue therapy during the study.
  • You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control.
  • You do not have certain other mental health conditions, such as bipolar disorder, schizophrenia, or a current substance misuse problem.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07002684Recruiting
Esketamine study for depression

This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.

Zagreb
NCT05973851Recruiting· Phase 3
Six-week medicine boost for depression after first treatment failure

This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.

Innsbruck
NCT07088380Recruiting· Phase 3
Ketamine combined with ECT for hard-to-treat depression

This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.

Milan
NCT06278779Recruiting· Phase 4
Comparing two types of ketamine for stubborn depression

This study compares two forms of ketamine to see which works better for depression that hasn't improved with at least two other antidepressants. If you've tried multiple antidepressants without success, this trial might help find a more effective treatment.

Camperdown, New South Wales
NCT07716098Recruiting· Phase 3
Esketamine nasal spray for treatment-resistant depression

This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.

Redlands, California
NCT06713616Recruiting· Phase 3
Esketamine vs. ketamine for hard-to-treat depression

This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.

Milford, Connecticut

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.